NEW YORK (360Dx) –  Roche said today that the US Food and Drug Administration has approved its Ventana ALK (D5F3) companion diagnostic as an aid in identifying ALK-positive non-small cell lung cancer patients who would benefit from treatment with the firm's drug Alecensa (alectinib).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.